$8.96
5.29%
Nasdaq, Nov 17, 03:59 pm EST. Closed.
ISIN
US9486261061
Symbol
WW

Weight Watchers International, Inc. Stock News

Neutral
●
GlobeNewsWire
●
about 10 hours ago
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced that it intends to utilize up to $10 million in cash to prepay a portion of its outstanding term loan at a discount through a voluntary solicitation of offers from its term loan lenders. The solicitation is e...
Neutral
●
GlobeNewsWire
●
12 days ago
Revenue of $153 million; Clinical Subscription Revenue of $38 million, up 48% year-over-year 2.3 million Total End of Period Subscribers; 40% year-over-year Clinical End of Period Subscriber growth to 174 thousand and 16% year-over-year Core+ End of Period Subscriber growth to 546 thousand Positive Net Income of $15.1 million, representing a 9.9% Net Income Margin; Adjusted EBITDA 1 of $51.7 mi...
Neutral
●
GlobeNewsWire
●
about 2 months ago
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) --  WW International, Inc. (NASDAQ: WW) ("Weight Watchers"), the global leader in science-backed weight management, today announced a collaboration with Google Health Enterprise, combining wearable technology and AI-powered health insights with Weight Watchers' clinically proven weight health program.
Neutral
●
Reuters
●
2 months ago
WW International on Wednesday named Stephen Bye as ​its chief executive officer, effective ‌this fall.
Neutral
●
GlobeNewsWire
●
2 months ago
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, announced today that it has appointed Stephen Bye as its President and Chief Executive Officer and a member of the Company's Board of Directors.
Neutral
●
GlobeNewsWire
●
3 months ago
Total End of Period Subscribers of 2.5 million; End of Period Clinical Subscribers of 197 thousand, up 55.7% year-over-year Core+ End of Period Subscribers of 541 thousand, up 13.9% year-over-year, reflecting third consecutive quarter of sequential growth Revenue of $162.3 million; Clinical Subscription Revenue of $39.9 million, up 30.4% year-over-year Reaffirms Full Year 2026 Financial Guidanc...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today